Novel ultrasensitive automated kinetic exclusion assay for measurement of plasma levels of soluble PD-L1, the predictive and prognostic biomarker in cancer patients treated with immune checkpoint inhibitors.

血浆或血清中可溶性程序性死亡配体1（PD-L1）水平被提出作为免疫检查点抑制剂治疗癌症患者的预测和预后生物标志物，但现有方法灵敏度、重现性和准确性有限。本研究开发超灵敏自动化流动式动力学排除分析（KinExA），用于血浆可溶性PD-L1的准确测量。基于KinExA™ 3200生物传感器，样品中PD-L1先与抗PD-L1单克隆抗体预平...